Quest Diagnostics (DGX) EBT (2009 - 2026)

Quest Diagnostics has disclosed EBT across 18 years of filings, most recently posting $334.0 million for Q1 2026.

• EBT for Q1 2026 came in at $334.0 million, up 21.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 16.12% YoY), and the FY2025 annual result was $1.3 billion, up 12.17% from the prior year.
• EBT came in at $334.0 million for Q1 2026 at Quest Diagnostics, up from $330.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $452.0 million in Q1 2022 to a low of $109.0 million in Q4 2022.
• The 5-year median for EBT is $314.0 million (2024), against an average of $305.4 million.
• Across the five-year window, EBT plunged 78.29% in 2022 and soared 117.43% in 2023, its largest moves.
• Quest Diagnostics' EBT stood at $109.0 million in 2022, then jumped by 117.43% to $237.0 million in 2023, then climbed by 26.16% to $299.0 million in 2024, then advanced by 10.37% to $330.0 million in 2025, then gained by 1.21% to $334.0 million in 2026.
• The last three EBT figures came in at $334.0 million (Q1 2026), $330.0 million (Q4 2025), and $328.0 million (Q3 2025), per Business Quant data.